Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
For years, prospective randomized clinical trials excluded patients with non-conventional histologies of renal cell carcinoma (RCC). The paucity of data has led to adopting the same treatment strategies used for clear-cell RCC (ccRCC). In the present narrative review, we explored state of the art ab...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2023-12, Vol.19 (1), p.2171672-2171672 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2171672 |
|---|---|
| container_issue | 1 |
| container_start_page | 2171672 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 19 |
| creator | Bersanelli, Melissa Rebuzzi, Sara Elena Roviello, Giandomenico Catalano, Martina Brunelli, Matteo Rizzo, Mimma |
| description | For years, prospective randomized clinical trials excluded patients with non-conventional histologies of renal cell carcinoma (RCC). The paucity of data has led to adopting the same treatment strategies used for clear-cell RCC (ccRCC). In the present narrative review, we explored state of the art about use of immune checkpoint inhibitors (ICIs) in variant histologies of RCC. According to the results collected, ICIs as monotherapy showed promising antitumor activity in advanced non-clear cell (ncc)RCC. The objective response rate (ORR) was similar to that observed with single-agent anti-PD-1 in the ccRCC population, either in the first-line or the second-line setting, and responder patients experienced an early and durable benefit. Combined ICI-based strategies have shown increasing evidence in nccRCC and robust results in the sarcomatoid variants of RCC. A definitive recommendation about treating non-conventional histologies, either in adjuvant or metastatic settings, should be supported by more extensive dedicated trials. |
| doi_str_mv | 10.1080/21645515.2023.2171672 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2023_2171672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_849ef6811d5645aba68a92a514be9161</doaj_id><sourcerecordid>2775624317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-51685833776d69a57301c643db863d551a44c8f40811efde52f586977505e67f3</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhlcIRKvSnwDaI5dN_W3vCVAFNFIlLkXiZk28duKy6wn2pqj_HoekEb3gi0fjd54Zz9s0bylZUGLIFaNKSEnlghHGF4xqqjR70Zzv852U4sfLU0zlWXNZyj2pRxMmlHrdnHGlpekVOW_ultO0S751G-9-bjGmuY1pE1dxxlxq2CZMncP04NMcMcHYbmKZccR19KXF0GZfk53z49g6yC4mnOBN8yrAWPzl8b5ovn_5fHd9091--7q8_nTbOcnl3EmqjDSca60G1YPUnFCnBB9WRvGhjg5COBMEMZT6MHjJgjSq11oS6ZUO_KJZHrgDwr3d5jhBfrQI0f5NYF5byHN0o7dG9D6oChpkXR2sQBnoGUgqVr6nilbWhwNru1tNfnD1vxnGZ9DnLylu7BofLCWEsp7xSnh_JGT8tfNltlMs-8VA8rgrltXBFROc6iqVB6nLWEr24dSHErt32D45bPcO26PDte7dv0Oeqp78rIKPB0FMAfMEvzGPg53hccQcMiQXi-X_7_EHoVu00Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2775624317</pqid></control><display><type>article</type><title>Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bersanelli, Melissa ; Rebuzzi, Sara Elena ; Roviello, Giandomenico ; Catalano, Martina ; Brunelli, Matteo ; Rizzo, Mimma</creator><creatorcontrib>Bersanelli, Melissa ; Rebuzzi, Sara Elena ; Roviello, Giandomenico ; Catalano, Martina ; Brunelli, Matteo ; Rizzo, Mimma</creatorcontrib><description>For years, prospective randomized clinical trials excluded patients with non-conventional histologies of renal cell carcinoma (RCC). The paucity of data has led to adopting the same treatment strategies used for clear-cell RCC (ccRCC). In the present narrative review, we explored state of the art about use of immune checkpoint inhibitors (ICIs) in variant histologies of RCC. According to the results collected, ICIs as monotherapy showed promising antitumor activity in advanced non-clear cell (ncc)RCC. The objective response rate (ORR) was similar to that observed with single-agent anti-PD-1 in the ccRCC population, either in the first-line or the second-line setting, and responder patients experienced an early and durable benefit. Combined ICI-based strategies have shown increasing evidence in nccRCC and robust results in the sarcomatoid variants of RCC. A definitive recommendation about treating non-conventional histologies, either in adjuvant or metastatic settings, should be supported by more extensive dedicated trials.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2023.2171672</identifier><identifier>PMID: 36758960</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>anti-PD-1 ; Antineoplastic Agents - therapeutic use ; Carcinoma, Renal Cell - drug therapy ; chromophobe renal cell carcinoma ; collecting duct carcinoma ; Humans ; immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapeutics – Review ; kidney cancer ; Kidney Neoplasms - drug therapy ; MiTF translocation ; nccRCC ; Non-clear cell renal carcinoma ; papillary renal cell carcinoma ; Prospective Studies ; Review ; Sarcomatoid RCC</subject><ispartof>Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2171672-2171672</ispartof><rights>2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023</rights><rights>2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-51685833776d69a57301c643db863d551a44c8f40811efde52f586977505e67f3</citedby><cites>FETCH-LOGICAL-c535t-51685833776d69a57301c643db863d551a44c8f40811efde52f586977505e67f3</cites><orcidid>0000-0002-6527-6281</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012923/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012923/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,27483,27905,27906,53772,53774,59122,59123</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36758960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bersanelli, Melissa</creatorcontrib><creatorcontrib>Rebuzzi, Sara Elena</creatorcontrib><creatorcontrib>Roviello, Giandomenico</creatorcontrib><creatorcontrib>Catalano, Martina</creatorcontrib><creatorcontrib>Brunelli, Matteo</creatorcontrib><creatorcontrib>Rizzo, Mimma</creatorcontrib><title>Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>For years, prospective randomized clinical trials excluded patients with non-conventional histologies of renal cell carcinoma (RCC). The paucity of data has led to adopting the same treatment strategies used for clear-cell RCC (ccRCC). In the present narrative review, we explored state of the art about use of immune checkpoint inhibitors (ICIs) in variant histologies of RCC. According to the results collected, ICIs as monotherapy showed promising antitumor activity in advanced non-clear cell (ncc)RCC. The objective response rate (ORR) was similar to that observed with single-agent anti-PD-1 in the ccRCC population, either in the first-line or the second-line setting, and responder patients experienced an early and durable benefit. Combined ICI-based strategies have shown increasing evidence in nccRCC and robust results in the sarcomatoid variants of RCC. A definitive recommendation about treating non-conventional histologies, either in adjuvant or metastatic settings, should be supported by more extensive dedicated trials.</description><subject>anti-PD-1</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>chromophobe renal cell carcinoma</subject><subject>collecting duct carcinoma</subject><subject>Humans</subject><subject>immune checkpoint inhibitors</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapeutics – Review</subject><subject>kidney cancer</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>MiTF translocation</subject><subject>nccRCC</subject><subject>Non-clear cell renal carcinoma</subject><subject>papillary renal cell carcinoma</subject><subject>Prospective Studies</subject><subject>Review</subject><subject>Sarcomatoid RCC</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU1vEzEQhlcIRKvSnwDaI5dN_W3vCVAFNFIlLkXiZk28duKy6wn2pqj_HoekEb3gi0fjd54Zz9s0bylZUGLIFaNKSEnlghHGF4xqqjR70Zzv852U4sfLU0zlWXNZyj2pRxMmlHrdnHGlpekVOW_ultO0S751G-9-bjGmuY1pE1dxxlxq2CZMncP04NMcMcHYbmKZccR19KXF0GZfk53z49g6yC4mnOBN8yrAWPzl8b5ovn_5fHd9091--7q8_nTbOcnl3EmqjDSca60G1YPUnFCnBB9WRvGhjg5COBMEMZT6MHjJgjSq11oS6ZUO_KJZHrgDwr3d5jhBfrQI0f5NYF5byHN0o7dG9D6oChpkXR2sQBnoGUgqVr6nilbWhwNru1tNfnD1vxnGZ9DnLylu7BofLCWEsp7xSnh_JGT8tfNltlMs-8VA8rgrltXBFROc6iqVB6nLWEr24dSHErt32D45bPcO26PDte7dv0Oeqp78rIKPB0FMAfMEvzGPg53hccQcMiQXi-X_7_EHoVu00Q</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Bersanelli, Melissa</creator><creator>Rebuzzi, Sara Elena</creator><creator>Roviello, Giandomenico</creator><creator>Catalano, Martina</creator><creator>Brunelli, Matteo</creator><creator>Rizzo, Mimma</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6527-6281</orcidid></search><sort><creationdate>20231231</creationdate><title>Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma</title><author>Bersanelli, Melissa ; Rebuzzi, Sara Elena ; Roviello, Giandomenico ; Catalano, Martina ; Brunelli, Matteo ; Rizzo, Mimma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-51685833776d69a57301c643db863d551a44c8f40811efde52f586977505e67f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>anti-PD-1</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>chromophobe renal cell carcinoma</topic><topic>collecting duct carcinoma</topic><topic>Humans</topic><topic>immune checkpoint inhibitors</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapeutics – Review</topic><topic>kidney cancer</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>MiTF translocation</topic><topic>nccRCC</topic><topic>Non-clear cell renal carcinoma</topic><topic>papillary renal cell carcinoma</topic><topic>Prospective Studies</topic><topic>Review</topic><topic>Sarcomatoid RCC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bersanelli, Melissa</creatorcontrib><creatorcontrib>Rebuzzi, Sara Elena</creatorcontrib><creatorcontrib>Roviello, Giandomenico</creatorcontrib><creatorcontrib>Catalano, Martina</creatorcontrib><creatorcontrib>Brunelli, Matteo</creatorcontrib><creatorcontrib>Rizzo, Mimma</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bersanelli, Melissa</au><au>Rebuzzi, Sara Elena</au><au>Roviello, Giandomenico</au><au>Catalano, Martina</au><au>Brunelli, Matteo</au><au>Rizzo, Mimma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2023-12-31</date><risdate>2023</risdate><volume>19</volume><issue>1</issue><spage>2171672</spage><epage>2171672</epage><pages>2171672-2171672</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>For years, prospective randomized clinical trials excluded patients with non-conventional histologies of renal cell carcinoma (RCC). The paucity of data has led to adopting the same treatment strategies used for clear-cell RCC (ccRCC). In the present narrative review, we explored state of the art about use of immune checkpoint inhibitors (ICIs) in variant histologies of RCC. According to the results collected, ICIs as monotherapy showed promising antitumor activity in advanced non-clear cell (ncc)RCC. The objective response rate (ORR) was similar to that observed with single-agent anti-PD-1 in the ccRCC population, either in the first-line or the second-line setting, and responder patients experienced an early and durable benefit. Combined ICI-based strategies have shown increasing evidence in nccRCC and robust results in the sarcomatoid variants of RCC. A definitive recommendation about treating non-conventional histologies, either in adjuvant or metastatic settings, should be supported by more extensive dedicated trials.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>36758960</pmid><doi>10.1080/21645515.2023.2171672</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-6527-6281</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2171672-2171672 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_21645515_2023_2171672 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | anti-PD-1 Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy chromophobe renal cell carcinoma collecting duct carcinoma Humans immune checkpoint inhibitors Immune Checkpoint Inhibitors - therapeutic use Immunotherapeutics – Review kidney cancer Kidney Neoplasms - drug therapy MiTF translocation nccRCC Non-clear cell renal carcinoma papillary renal cell carcinoma Prospective Studies Review Sarcomatoid RCC |
| title | Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A01%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20checkpoint%20inhibitors%20in%20non-conventional%20histologies%20of%20renal-cell%20carcinoma&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Bersanelli,%20Melissa&rft.date=2023-12-31&rft.volume=19&rft.issue=1&rft.spage=2171672&rft.epage=2171672&rft.pages=2171672-2171672&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2023.2171672&rft_dat=%3Cproquest_cross%3E2775624317%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2775624317&rft_id=info:pmid/36758960&rft_doaj_id=oai_doaj_org_article_849ef6811d5645aba68a92a514be9161&rfr_iscdi=true |